TPD & Induced Proximity Summit Leaderboard
  • Monday, August 17, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 29

Author

Pharma Journalist 9001 posts 0 comments

Sidewinder Therapeutics Secures $137M to Advance Cancer Therapies

Apr 9, 2026
Sidewinder Therapeutics has announced the successful close of an oversubscribed $137 million Series B financing round, marking a significant milestone for the emerging biopharmaceutical…
Read More...

Shionogi Wins U.S. Contract to Advance Fetroja Antibiotic

Apr 8, 2026
Shionogi & Co., Ltd. has secured a major U.S. government contract to expand the development and supply of its antibiotic Fetroja, reinforcing efforts to combat drug-resistant…
Read More...

Alloy, Biogen Partner on Next-Gen Antisense Therapies

Apr 8, 2026
Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance the development of next-generation antisense therapeutics targeting multiple…
Read More...

Neurocrine to Acquire Soleno in $2.9 Billion Deal

Apr 8, 2026
Neurocrine Biosciences, Inc. has entered into a definitive agreement to acquire Soleno Therapeutics, Inc. in an all-cash transaction valued at approximately $2.9 billion, marking a…
Read More...

Apnimed Secures $150M to Advance Sleep Apnea Drug Launch

Apr 8, 2026
Apnimed, Inc. has secured a senior secured credit facility of up to $150 million from funds managed by HealthCare Royalty Partners, providing a major financial boost as the company…
Read More...

Akari Partners with WuXi XDC on Novel Cancer Therapy

Apr 7, 2026
Akari Therapeutics Plc has announced a strategic partnership with WuXi XDC to accelerate the development of its next-generation antibody-drug conjugate (ADC) technology, marking a…
Read More...

Lilly to Acquire Centessa in $6.3 Billion Deal

Apr 1, 2026
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with additional…
Read More...

Teva Advances Biosimilars With FDA Approval and Filings

Apr 1, 2026
Teva Pharmaceutical Industries has announced a series of significant milestones in its biosimilars portfolio, underscoring progress in its broader “Pivot to Growth” strategy and…
Read More...

Symeres, Ambagon Partner on Novel Cancer Drug Approach

Apr 1, 2026
Symeres has entered into a strategic collaboration with Ambagon Therapeutics to explore a promising new class of small molecules known as molecular glues for the treatment of colorectal…
Read More...

Biogen to Acquire Apellis in $5.6 Billion Deal

Apr 1, 2026
Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...
Prev Next
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
Neuropsychiatric Drug Development Summit
10th IPF Summit
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
Cell & Gene Therapy Summit South Korea
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
TRP Supply Chain & Manufacturing Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Aurisco Passes FDA Inspection for Generic Oligonucleotide APIs
  • Alfasigma to Acquire Nordic Pharma in Global Expansion
  • Lilly Files Six Lawsuits Against Black-Market Retatrutide Sellers
  • Ivonescimab Wins China Approval for First-Line Squamous NSCLC
  • Sentynl, Mereo Partner to Advance Oral AATD Lung Disease Therapy

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

2nd T-Cell Engager for Autoimmune Disease Summit Returns in…

New Era for Autoimmune T-Cell Engagers Takes Centre Stage…

From Innovation to Acquisition: CrossBridge Bio’s ADC…

COPD Foundations Joins the COPD Drug Development Summit

Advancing Respiratory Medicine Following ATS – What Now?

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.